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Background: This study explores variables associated with poor prognosis in postoperative p16 positive
oropharyngeal squamous cell carcinoma (OPSCC) patients undergoing adjuvant radiotherapy or chemoradiotherapy.
Specifically, analysis was done related to timing of feeding tube insertion relative to radiotherapy.
Methods: From 1997–2009, of 376 consecutive patients with OPSCC, 220 received adjuvant IMRT, and 97 were p16
positive and eligible. Of these, 23 had feeding tube placement before IMRT (B-FT), 32 during/after IMRT (DA-FT), and 42
had no feeding tube (NO-FT). Feeding tubes were not placed prophylactically. These three groups were analyzed for
differential tumor, patient, treatment, and feeding tube characteristics, as well as differences in overall survival (OS),
disease free survival (DFS), and distant metastasis free survival (DMFS).
Results: Pre-RT FT insertion was associated with higher tumor size and depth, T (but not N) and overall stage,
comorbidities, presence of chemotherapy, and less use of transoral laser microsurgery/transoral bovie. Additionally, time
from surgery to IMRT completion was also statistically longer in the B-FT group. The feeding tube was permanent in
52% of patients in the B-FT group versus 16% in the DA-FT group (p = 0.0075). The 5-year OS for the NO-FT, DA-FT, and
B-FT groups was 90%, 86%, and 50%, respectively. The 5-year DFS for the NO-FT, DA-FT, and B-FT groups was 87.6%,
83.6%, and 42.7%, respectively. Multivariate analysis showed that for OS and DFS, feeding tube placement timing and
smoking history were statistically significant.
Conclusion: Due to the poor prognosis of early FT insertion, the presence of FTs at time of radiotherapy consultation
can be used as an alternate marker to identify a subset of p16 positive OPSCC patients that have a poor prognosis.
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Feeding tube placement for patients with head and neck
cancer undergoing radiation therapy (RT) aims to mini-
mize weight loss and maintain nutrition secondary to RT
induced mucositis, odynophagia, and/or nausea [1]. Al-
though intensity-modulated radiation therapy (IMRT) at-
tempts to minimize side effects, 50-70% of patients
require a feeding tube after chemoradiotherapy, 15-40%* Correspondence: hgay@radonc.wustl.edu
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unless otherwise stated.with RT alone, and 20-40% with surgery followed by ad-
juvant RT [2]. In addition to patient comfort, the use of
percutaneous endoscopic gastrostomy (PEG) tubes has
replaced nasogastric tubes due to better control of weight
post-insertion [3].
Prophylactic PEG tube insertion for head and neck
cancer patients has been a topic of much controversy
[2]. Prophylactic feeding tube proponents note that
prophylactic placement not only limits weight loss, espe-
cially in advanced unresectable patients [4], but also im-
proves 6-month quality of life [5]. In addition, patients
with prophylactically-placed feeding tubes may suffer
less morbidity and hospitalizations [6]. On the otherThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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of unnecessary placement (almost 50% per the defini-
tions of Madhoun et al. [7]), and a higher likelihood of
prolonged or permanent dependence, especially with ad-
vanced T-stage and pre-existing dysphagia [8]. To ad-
dress these issues, many centers like ours have adopted
a “reactive strategy” for feeding tube placement. This
plan uses dedicated oral nutritional supplements very
early, with strict nutritional follow-up such that if
center-dependent nutritional maintenance requirements
are not being fulfilled, the patient undergoes feeding tube
placement.
In this study we focused on surgically treated p16 posi-
tive OPSCC patients who received adjuvant radiotherapy
or chemoradiotherapy, a group with overall good progno-
sis due to human papillomavirus (HPV) related disease. In
these patients, feeding tube placement is often assumed to
be a consequence of adjuvant radiotherapy or adjuvant
chemoradiotherapy, and the prognostic significance of
feeding tube placement at various time points is not well
understood. The present study identifies a subset of this
patient population with a poor prognosis, as related to




A total of 376 consecutive patients with OPSCC were
available for analysis from the years 1997–2009 in our
prospective head and neck radiotherapy registry. The
diagnosis of SCC was based on report review from the
pathology interpreted in routine practice. This included
known histologic variants of SCC. Of these patients, 220
underwent postoperative IMRT. Of these 220 patients,
p16 status was known in 124 patients, with 104 being
p16 positive. Ninety-nine of the p16 positive patients
were stage III or IV; two were eliminated due to non-
oncologic surgery, which left 97 patients for analysis. Be-
cause p16 positive OPSCC generally has a better prognosis
than p16 negative disease, we sought to find subgroups of
p16 positive OPSCC patients that may do poorly, and thus
considered only p16 positive patients. Feeding tubes were
not placed prophylactically. Feeding tube placement was
left at the discretion of the managing physician (surgeon,
medical oncologist, or radiation oncologist), and the deci-
sion was based on the patient’s nutritional status and
symptoms.
p16 Immunohistochemistry
Immunohistochemistry was performed on 4 μm sections
from formalin-fixed, paraffin-embedded tissue blocks
using an antibody to p16 (MTM Laboratories; monoclo-
nal; 1:1 dilution) on a Ventana Benchmark LT automated
immunostainer (Ventana Medical Systems, Inc., Tucson AZ)according to standard protocols. Antigen retrieval, stand-
ard on the machine, utilized the Ventana CC1, EDTA-
Tris, pH 8.0 solution. A known p16 expressing head and
neck squamous cell carcinoma or ovarian papillary serous
carcinoma case was used as a positive control with each
run.
Cases were reviewed independently by the study path-
ologist without knowledge of the other features of the
cases and were classified in quartiles by the extent of
cells having both nuclear and cytoplasmic staining as: 0 =
no staining; 1+ = 1 to 25% of tumor cells positive; 2+ = 26
to 50%; 3+ = 51 to 75%; 4+ = >76%. Results were divided
using a 50% cutoff into negative (0, 1+, or 2+) and posi-
tive (3+ or 4+) based on data showing the correlation
between extensive p16 expression and the presence of
transcriptionally-active HPV [9].
Surgery
The majority of resectable patients at our institution
undergo surgery, preferably transoral laser microsurgery
(TLM), so we focused our analysis on p16+ postopera-
tive patients receiving adjuvant radiotherapy, thus pro-
viding a unique analysis. Surgical approaches included
TLM (57%), as per the principles of Steiner and Ambrosch
[10]), transoral bovie approach (21%), or “other” (22%)
which included: open mandibulotomy or pharyngotomy, a
combination of open and transoral laser or bovie ap-
proaches; or transoral ‘cold steel’. The approach was based
on surgeon judgment considering the tumor size and loca-
tion, degree of involvement of nearby structures, and
adequacy of transoral access. Neck dissections were
generally performed at the time of primary tumor extir-
pation. Patients underwent appropriate reconstruction
when necessary.
Chemotherapy
Platinum-based chemotherapy (mostly cisplatin 100 mg/m2
on days 1, 22, and 43 of RT) was delivered to 43 patients
and cetuximab 400 mg/m2 loading dose followed by
250 mg/m2 weekly × 8 to 3 patients. The use of chemo-
therapy or cetuximab was based on high-risk pathologic
factors such as: ECE, positive margins, pT3/T4, pN2/N3,
perineural invasion, and vascular embolism.
Radiation therapy
Patients were supine and immobilized using a thermo-
plastic mask. As technology evolved, fusion of PET/CT
and/or MRI scans to the planning CT helped define the
clinical tumor volumes (CTVs), as well as clinical and
pathologic information. In general, CTV1 encompassed
the high-risk volume which consisted of the pre-operative
primary GTV with a 1.5 cm margin for potential micro-
scopic spread and any involved lymph node levels plus a
0.5 cm to 1 cm margin; CTV2 corresponded to electively
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or AP/PA supraclavicular field used at the beginning of
our IMRT program. One CTV was defined for 31% of
patients, two CTVs for 56% of patients, and three CTVs
for 13% of patients. The median dose (range) for CTV1,
CTV2, and CTV3 were 66 (60–70) Gy, 56 (54–66.6) Gy
and 56 (54 – 56) Gy, respectively. PTVs were defined by
adding 0.5 cm to the corresponding CTVs and subtracting
3 mm from the skin.
Statistical analysis
The primary endpoints were overall survival (OS), dis-
ease free survival (DFS), and distant metastases free sur-
vival (DMFS). OS was defined as the time from IMRT
completion to death from any cause or last follow-up.
DFS was defined as the time from IMRT completion to
locoregional failure (LRF), distant metastasis or death
from any cause, whichever came first. For the patients
without any above events, it was defined as the time
from IMRT completion to last follow-up. DMFS was de-
fined as the time from IMRT completion to the develop-
ment of distant metastasis or last follow-up. Duration of
feeding tube was defined as the time from feeding tube in-
sertion to removal if the feeding tube was not permanent,
and to last follow-up otherwise. Swallow studies were ob-
tained at the discretion of the managing physician(s) after
RT for assessment of swallowing dysfunction.
SAS Version 9.3 (Cary, NC) was used to perform all
statistical analyses. Continuous and categorical variables
were compared by a Kruskal-Wallis test and the Fisher
Exact (or chi-square) test, respectively. Kaplan-Meier
(KM) curves were generated that provide unadjusted
survival estimates for all patients and across strata. Dif-
ferences between strata were determined by log-rank
tests. Univariate and multivariate analyses through Cox
proportional-hazards models were considered to evalu-
ate the interested variables for OS, DFS and DMFS. The
proportionality assumption was tested by adding a time-
dependent covariate for each variable. A backward step-
wise model selection approach was performed to identify
all significant risk factors. Factors significant at a 10%
level were kept in the final model. All statistical tests
were two-sided using an α = 0.05 level of significance.
Results
Patient, tumor, and management characteristics
Tables 1, 2, and 3 summarize the patient and tumor
characteristics for the NO-FT (43% of patients), B-FT
(24%), and DA-FT (33%) groups. Of note, the feeding
tube was permanent in 52% of patients in the B-FT
group versus 16% in the DA-FT group (p = 0.0075). The
locoregional relapse rate for the entire group was 2%. The
two patients who failed only received adjuvant radiother-
apy versus adjuvant chemoradiotherapy.Feeding tube placement was associated with the type
of surgery, pathologic T stage, pathologic stage, ACE-27
score, and chemotherapy. Patients in the B-FT group
had the highest percentage of patients with “other” type
of surgeries (69.6%), T4a tumors (43.5%), stage IVa tumors
(95.7%), and moderate/severe ACE-27 scores (31.8%).
There was a statistically significant difference in the
median tumor size, depth, and time from surgery to com-
pletion of IMRT among the three groups. Patients in the
B-FT group had the largest median tumor size (4 cm) and
depth (1.2 cm), and longest median time to complete
IMRT (107 days).
Feeding tube placement was not associated with gen-
der, race, alcohol use, smoking status, margin status,
tumor laterality and location, perineural invasion, vascu-
lar invasion, lymphatic invasion, extracapsular extension,
soft tissue metastases, N stage, or aspiration observed in
a swallow study. There was no statistically significant
difference in age, BMI at time of tube placement, rate of
weight loss prior to RT, or duration of feeding tube
among groups.Kaplan-Meier plot
There was a statistically significant difference in OS
(Figure 1A) and DFS (Figure 1B) among the three groups
(p <0.0001 for both), but not in DMFS (Figure 1C) (p =
0.9981). The 5-year OS for the NO-FT, DA-FT, and B-FT
groups was 90%, 86%, and 50%, respectively. The 5-year
DFS for the NO-FT, DA-FT, and B-FT groups was 87.6%,
83.6%, and 42.7%, respectively. The 5-year DMFS for the
NO-FT, DA-FT, and B-FT groups was 90.3%, 89.5%, and
89.5%, respectively. Additionally, there was a statistically
significant difference (p < 0.0001) if the NO-FT and DA-
FT groups were combined and compared to the B-FT
group in terms of both OS and DFS.Univariate analysis
On univariate analysis through Cox-proportional hazards
models (Table 4), significant predictors of DFS and OS on
univariate analysis included: feeding tube group, age,
smoking status, and type of surgery performed. T-stage
and ACE-27 score were significant factors for OS only.Multivariate analysis
As shown in Table 5, the only predictors of both OS and
DFS on multivariate analysis were feeding tube group
and smoking status. Specifically, the B-FT group had a
6.0 HR (2.0 - 18.6, 95% CI) for OS and 4.7 HR (1.7 -
13.1, 95% CI) for DFS when compared to the NO-FT
group. The ≥ 20 pack-years smoking group had a 5.0 HR
(1.6 - 15.3, 95% CI) for OS and 3.8 HR (1.4 - 10.6, 95%
CI) for DFS when compared to the never smoker group.
Table 1 Patient characteristics for the three patient groups








Median (range) (y) 54 (32 – 73) 57 (48 – 67) 54 (37 – 72) 0.35
Gender
Male 40 (95.2%) 21 (91.3%) 31 (96.9%) 0.72
Female 2 (4.8%) 2 (8.7%) 1 (3.1%)
Race
Caucasian 40 (95.2%) 22 (95.7%) 32 (100%) 0.46
African-American 2 (4.8%) 1 (4.3%) 0 (0%)
Alcohol Use
Rarely or Never 22 (56.4%) 13 (56.5%) 17 (53.1%) 0.51
Occasional 8 (20.5%) 3 (13.0%) 10 (31.3%)
Heavy 9 (23.1%) 7 (30.4%) 5 (15.6%)
Smoking Status
Never Smoker 21 (51.2%) 8 (34.8%) 9 (28.1%) 0.29
<20 pack-years 5 (12.2%) 4 (17.4%) 4 (12.5%)
≥20 pack-years 15 (36.6%) 11 (47.8%) 19 (59.4%)
ACE-27 Score
None/Mild 38 (95.0%) 15 (68.2%) 23 (74.2%) 0.0076
Moderate/Severe 2 (5.0%) 7 (31.8%) 8 (25.8%)
BMI at time of tube placement
Median (range) N/A 26.5 (20.0 – 31.0) 24.5 (15.7 – 41.2) 0.12
Rate of weight loss prior to IMRT (− lbs/mo loss; + is gain)
Median (range) −6.9 (−19.0 – +5.0) −10.6 (−20 – +0.6) −1.2 (−12 – +2.8) 0.36
Swallow Studies
Aspiration 10 (76.9%) 18 (85.7%) 14 (77.8%) 0.74
No aspiration 3 (23.1%) 3 (14.3%) 4 (22.2%)
Abbreviations: ACE-27 Adult Comorbidity Evaluation-27.
Bold p-values indicate statistical significane at p < 0.05.
Verma et al. Radiation Oncology  (2015) 10:8 Page 4 of 10Causes of death
At last follow-up, 24 (25%) patients had died. The causes
of death in the B-FT group were as follows: locoregional
disease, 2 (9%); distant metastases, 1 (4%); second primary,
5 (22%); and 5 (22%) of all other causes. The causes of
death in the DA-FT group were as follows: distant metas-
tases, 2 (6%); second primary, 1 (3%); and 3 (9%) of all
other causes. The causes of death in the NO-FT group
were as follows: distant metastases, 3 (7%); second pri-
mary, 1 (2%); and 1 (2%) of all other causes. Out of the
seven patients with second primary tumors, five were lung
cancer, one esophageal cancer, and one with auditory canal
squamous cell carcinoma.
Reasons for feeding tube placement
The physician decision to place a feeding tube has both
objective and subjective criteria based on clinical experi-
ence. Our policy is to delay feeding tubes as clinicallyfeasible without compromising the patients’ health. At
our center, the patients’ weight is monitored weekly. Pa-
tients are also evaluated by a nutritionist weekly. If the
patients’ weight drop is between 5 to 10%, or if patients
experience symptoms such as not being able to eat and/
or drink for more than 24 hours, the reasoning for FT
placement is mostly due to poor PO intake. Other more
subjective patient factors such as the severity of dyspha-
gia and/or odynophagia also influenced the decision.
Based on these factors the physician has a conversation
regarding feeding tube placement. Some patients agree
at this point to proceed with a feeding tube, while others
opt to delay the feeding tube hoping they can increase
their caloric intake. Patients who delay the feeding tubes
often have further drops in weight.
Poor nutritional status was the most common reason
for feeding tube placement in the B-FT group (77.3%),
followed by dysphagia alone (9.1%), poor PO intake
Table 2 Tumor characteristics for the three patient groups
Characteristic No feeding tube (n = 42) Tube before RT (n = 23) Tube during/after RT (n = 32) p-value
Tumor Location
Tonsil 23 (54.8%) 8 (34.8%) 18 (56.3%) 0.23
Base of Tongue 18 (42.9%) 12 (52.2%) 11 (34.4%)
Other 1 (2.4%) 3 (13.0%) 3 (9.4%)
Tumor Laterality
Right 21 (50.0%) 9 (39.1%) 17 (53.1%) 0.67
Left 18 (42.9%) 11 (47.8%) 14 (43.8%)
Bilateral 3 (7.1%) 3 (13.0%) 1 (3.1%)
Perineural Invasion
Yes 3 (8.8%) 7 (31.8%) 4 (14.3%) 0.089
No 31 (91.2%) 15 (68.2%) 24 (85.7%)
Vascular Invasion
Yes 10 (27.0%) 8 (25%) 3 (11.1%) 0.095
No 27 (73.0%) 14 (75%) 24 (88.9%)
Lymphatic Invasion
Yes 16 (43.2%) 15 (68.2%) 10 (34.5%) 0.054
No 21 (56.8%) 7 (31.8%) 19 (65.5%)
Extracapsular Extension
Positive 35 (87.5%) 21 (91.3%) 26 (81.3%) 0.56
Negative 5 (12.5%) 2 (8.7%) 6 (18.7%)
Soft Tissue Metastases
Yes 20 (64.5%) 14 (66.7%) 17 (65.4%) 1.00
No 11 (35.5%) 7 (33.3%) 9 (34.6%)
Tumor Size (cm)
Median (range) 2.0 (0.2 – 6.0) 4.0 (1.2 – 12.0) 2.25 (0.5 – 6.6) 0.0014
Tumor Depth (cm)
Median (range) 0.75 (0.05 – 5.0) 1.2 (0.45 – 4.5) 0.65 (0.12 – 1.9) 0.014
Pathologic T stage
T1 23 (54.8%) 2 (8.7%) 13 (40.6%) <0.0001
T2 14 (33.3%) 5 (21.7%) 17 (53.1%)
T3 3 (7.1%) 6 (26.1%) 2 (6.3%)
T4a 2 (4.8%) 10 (43.5%) 0 (0%)
Largest Lymph Node (cm)
Median (range) 3.0 (1.3 – 6.0) 3.7 (0.7 – 6.0) 3.3 (0.6 – 7.5) 0.67
Total Number of Metastatic Lymph Nodes
Median (range) 2 (1 – 15) 4 (1 – 25) 2 (1 – 40) 0.19
Pathologic N stage
N1 9 (21.4%) 2 (8.7%) 7 (21.9%) 0.072
N2a 9 (21.4%) 4 (17.4%) 2 (6.3%)
N2b 20 (47.6%) 11 (47.8%) 16 (50.0%)
N2c 4 (9.5%) 6 (26.1%) 3 (9.4%)
N3 0 (0%) 0 (0%) 4 (12.5%)
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Table 2 Tumor characteristics for the three patient groups (Continued)
Pathologic stage
III 9 (21.4%) 1 (4.3%) 7 (21.9%) 0.016
IVA 33 (79.6%) 22 (95.7%) 21 (65.6%)
IVB 0 (0%) 0 (0%) 4 (12.5%)
Bold p-values indicate statistical significane at p < 0.05.
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Poor PO intake was the most common reason for feed-
ing tube placement in the DA-FT group (28.1%), fol-
lowed by dysphagia (18.8%), dysphagia + odynophagia +
poor PO intake (15.6%), dysphagia + poor PO intake
(9.4%), dysphagia + weight loss (9.4%), dysphagia + ody-
nophagia + poor PO intake + weight loss (9.4%), poor PO
intake + weight loss (3.1%), odynophagia + poor PO in-
take + weight loss (3.1%), and weight loss alone (3.1%).
Discussion
Patients with p16 positive OPSCC have a relatively good
prognosis [11]. However, in our 97 patient group, we
were able to identify a subset of 23 patients who had the
feeding tube placed prior to IMRT (of note, we followedTable 3 Management characteristics for the three patient gro
Type of Surgery
Transoral Laser 28 (66.7%)








Time from Surgery to Completion of RT (days)
Median (range) 91 (74 – 135)
Duration of feeding tube (mo)
Median (range) N/A




Locoregional Disease 0 (0%)
Distant Metastatic Disease 3 (60%)
Second Primary 1 (20%)
All Other Causes 1 (20%)
Abbreviations: TLM transoral laser microsurgery.
*One of the following: open mandibulotomy; open pharyngotomy; open pharyngot
mandibulotomy and transoral CO2 laser; open pharyngotomy; and transoral ‘cold st
Bold p-values indicate statistical significane at p < 0.05.a reactive rather than prophylactic feeding tube place-
ment policy which is important when interpreting the
results). These patients had a significantly worse progno-
sis with a 50% 5-year overall survival, compared to
88.3% for the rest of the group. In this patient popula-
tion, T-stage has been a significant factor for OS and
DFS [12,13]. However, in our multivariate analysis, feed-
ing tube grouping was significant, while T stage was not.
The reason for this is not clear, but it may be that the
poor prognosis B-FT group has more poor-prognostic
variables. Specifically, patients in the B-FT group had
the highest percentage of patients with “other” type of
surgeries (requiring open approaches versus exclusively
minimally invasive approaches), T4a tumors, stage IVA
tumors, and moderate/severe ACE-27 scores. Our resultsups
6 (26.1%) 21 (65.6%) <0.0001
1 (4.3%) 10 (31.3%)
16 (69.6%) 1 (3.1%)
3 (13.6%) 4 (13.8%) 0.85
19 (86.4%) 25 (86.2%)
14 (56.0%) 20 (62.5%) 0.0050
9 (44.0%) 12 (37.5%)
107 (85 – 140) 92 (81 – 144) 0.0008
7.27 (3.91 – 40.53) 5.1 (1.68 – 22.96) 0.069
12 (52.2%) 5 (16.1%) 0.0075
11 (47.8%) 26 (83.9%)
2 (15.4%) 0 (0%) 0.36
1 (7.7%) 2 (33.3%)
5 (38.5%) 3 (50%)
5 (38.5%) 1 (16.7%)
omy and transoral CO2 laser; open pharyngotomy and transoral bovie; open
eel’.
Figure 1 Overall survival (A), disease free survival (B), and distant metastases free survival (C) for the no feeding tube (NO-FT), before
IMRT feeding tube (B-FT), and during or after IMRT feeding tube (DA-FT).
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Table 4 Univariate analysis for overall survival, disease
free survival, and distant metastases
Overall survival p-value
FT Group
B-FT vs. NO-FT 0.0003
DA-FT vs. NO-FT
Age (years)
≥50 vs. < 50 0.0435
Smoking
<20 pack-years vs. never smoker 0.0272
≥20 pack-years vs. never smoker
Type of Surgery
TLM vs. other 0.0024*
transoral bovie vs. other
ACE Score
Moderate/ Severe vs. Mild/None 0.0253*
Combined T Stage




B-FT vs. NO-FT 0.0004
DA-FT vs. NO-FT
Age (years)
≥50 vs. < 50 0.0374
Smoking
<20 pack-years vs. never smoker 0.0346
≥20 pack-years vs. never smoker
Type of Surgery
TLM vs. other 0.0024*
transoral bovie vs. other
ACE Score
Moderate/Severe vs. Mild/None 0.0675*
Combined T Stage
T1 vs. T3/T4 0.0509*
T2 vs. T3/T4
Distant Metastases Free Survival
Group
B-FT vs. NO-FT 0.9981
DA-FT vs. NO-FT
Age (years)
≥50 vs. < 50 0.1060
Abbreviations: B-FT Feeding tube placement before IMRT, DA-FT Feeding tube
placement during or after IMRT, NO-FT No feeding tube, TLM Transoral laser
microsurgery, CI Confidence interval.
*Significant in univariate but not in multivariate analysis.
Table 5 Multivariate analysis for overall survival, disease
free survival, and distant metastases
Overall survival HR (95% CI) p-value
FT Group
B-FT vs. NO-FT 6.0 (2.0 – 18.6) 0.0013
DA-FT vs. NO-FT 1.5 (0.4 – 5.4)
Age (years)
≥50 vs. < 50 2.1 (0.8 – 5.3) 0.1165
Smoking
<20 pack-years vs. never smoker 3.6 (0.8 – 16.9) 0.0182
≥20 pack-years vs. never smoker 5.0 (1.6 – 15.3)
Disease Free Survival
FT Group
B-FT vs. NO-FT 4.7 (1.7 – 13.1) 0.0017
DA-FT vs. NO-FT 1.3 (0.4 – 4.0)
Age (years)
≥50 vs. < 50 2.3 (1.0 – 5.4) 0.0619
Smoking
<20 pack-years vs. never smoker 2.2 (0.5 – 9.5) 0.0316
≥20 pack-years vs. never smoker 3.8 (1.4 – 10.6)
Distant Metastases Free Survival
Group
B-FT vs. NO-FT 0.91 (0.17 – 5.02) 0.9942
DA-FT vs. NO-FT 0.95 (0.21 – 4.27)
Age (years)
≥50 vs. < 50 3.7 (0.8 – 17.8) 0.1053
Abbreviations: B-FT Feeding tube placement before IMRT, DA-FT Feeding tube
placement during or after IMRT, NO-FT No feeding tube, TLM Transoral laser
microsurgery, CI Confidence interval.
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are more likely to be inserted in patients with more
advanced disease and comorbidities [14].
Patients in the B-FT group also had the largest median
tumor size and depth, and longest median time to
complete IMRT, 107 days (more than two weeks com-
pared to the median of the other 2 groups). An overall
treatment length ≥ 100 days has been associated with a
worse local control and survival [15]. Similarly, the me-
dian (range) days from surgery to start of IMRT was lon-
gest for the B-FT group at 57 (34 – 94) days, compared
to the NO-FT group at 46 (30 – 84) days and the DA-
FT group at 44.5 (32 – 93) days. However, in this study
only 2 patients died from locoregional disease, which
does not support the hypothesis that longer treatment
times or higher T stage, variables associated with a
higher risk of local recurrence, explain the worse prog-
nosis of the B-FT group.
The magnitude of these patient and tumor characteris-
tics or delay in IMRT completion in treatment outcomes
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completion has the biggest impact, then surgery may be
suboptimal for some of these patients. Although a direct
comparison is not possible between the B-FT group and
non-surgical series, the 3-year OS [16,17] in predomin-
antly definitively treated patients with IMRT has ranged
between 78 and 83%, compared to the 64.7% 3-year OS
in the B-FT group.
Contrary to popular belief, 24% of patients had a feed-
ing tube inserted prior to IMRT, while 33% of patients
had it during or after IMRT. In addition, the feeding
tube was permanent in 52% of patients who had the
feeding tube inserted prior to IMRT, versus 16% in the DA-
FT group. Patients with a feeding tube at the time of radi-
ation oncology consult should be counseled accordingly.
Another implication of this study is that because the
presence of a pre-RT FT was associated with poor prog-
nostic factors and variables associated with a higher risk
of FT placement (such as comorbidities, T and overall
stage, chemotherapy), the presence of a FT at time of ra-
diation oncology consultation can be effectively used as
a quick but reliable indicator of worse disease status in
patients with p16 positive OPSCC. This use of a surro-
gate marker should alert clinicians that the patient is
part of a higher-risk subgroup of p16 positive OPSCC
with relatively worse prognosis.
The B-FT group did not have a higher risk of aspir-
ation (p = 0.74) during swallowing studies compared to
the other groups which could have explained the in-
crease in mortality. There was no statistically significant
difference (p = 0.36) in the cause of death among the 3
groups. This suggests that the feeding tube insertion
prior to IMRT is of prognostic significance and not re-
sponsible for the increased mortality in this group. One
area of further investigation will be to predict which pa-
tients have the highest risk of requiring a feeding tube at
the time of surgery.
Conclusion
Due to the poor prognosis of early FT insertion, the
presence of FTs at time of radiotherapy consultation can
be used as an alternate marker to identify a subset of
p16 positive OPSCC patients that have a relatively poor
prognosis.
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